Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology - 10/10/20
, Kristin Rentzsch cAbstract |
Background |
The current standard in the serologic diagnosis of autoimmune bullous diseases (AIBD) is a multistep procedure sequentially applying different assays. In contrast, the BIOCHIP Mosaic technology combines multiple substrates for parallel analysis by indirect immunofluorescence.
Methods |
Sera from 749 consecutive, prospectively recruited patients with direct immunofluorescence–positive AIBD from 13 international study centers were analyzed independently and blinded by using (1) a BIOCHIP Mosaic including primate esophagus, salt-split skin, rat bladder, monkey liver, monkey liver with serosa, recombinant BP180 NC16A, and gliadin GAF3X, as well as HEK293 cells expressing recombinant desmoglein 1, desmoglein 3, type VII collagen, and BP230 C-terminus and (2) the conventional multistep approach of the Department of Dermatology, University of Lübeck.
Results |
In 731 of 749 sera (97.6%), specific autoantibodies could be detected with the BIOCHIP Mosaic, similar to the conventional procedure (725 cases, 96.8%). The Cohen κ for both serologic approaches ranged from 0.84 to 1.00. In 6.5% of sera, differences between the 2 approaches occurred and were mainly attributed to autoantigen fragments not present on the BIOCHIP Mosaic.
Limitations |
Laminin 332 and laminin γ1 are not represented on the BIOCHIP Mosaic.
Conclusions |
The BIOCHIP Mosaic is a standardized time- and serum-saving approach that further facilitates the serologic diagnosis of AIBD.
El texto completo de este artículo está disponible en PDF.Graphical abstract |
Key words : autoimmune bullous diseases, biochip, immunofluorescence, pemphigoid, pemphigus
Abbreviations used : Aab, AIBD, BP, Dsg, EBA, IF
Esquema
| Mrs Krüger and Mr Fuhrmann contributed equally to this article. Drs Schmidt and Rentzsch contributed equally to this article. |
|
| Funding sources: Supported by Deutsche Forschungsgemeinschaft through the Research Training Group 1727 Modulation of Autoimmunity (to Mrs Krüger and Mr Fuhrmann), the Clinical Research Unit 303 Pemphigoid Diseases (to Drs van Beek, Zillikens, and Schmidt), the Schleswig-Holstein Cluster of Excellence Inflammation at Interfaces (EXC 306/2 to Drs Zillikens and Schmidt), and a research grant of EUROIMMUN, Lübeck, Germany, including free provision of BIOCHIP Mosaics (to Dr Schmidt). |
|
| Disclosure: Drs Probst, Komorowski, Fechner, and Rentzsch are employees of and Dr Stöcker is a board member of EUROIMMUN. Drs Zillikens and Schmidt have a scientific cooperation with EUROIMMUN. Dr van Beek, Mrs Krüger, Mr Fuhrmann, and Drs Lemcke, Goletz, Di Zenzo, Dmochowski, Drenovska, Horn, Jedlickova, Kowalewski, Medenica, Murrell, Patsatsi, Geller, Uzun, Vassileva, and Zhu have no conflicts of interest to declare. |
|
| IRB approval status: Reviewed and approved by the ethics committee of the University of Lübeck (#11-078). |
Vol 83 - N° 5
P. 1315-1322 - novembre 2020 Regresar al número
Artículo precedente
- Treatment of keloids with a single dose of low-energy superficial X-ray radiation to prevent recurrence after surgical excision: An in vitro and in vivo study
- Yuna Son, Ernest Owen Nicandro Phillips, Kristin Magrini Price, Laurence Zalmon Rosenberg, Branko Stefanovic, Christopher Michael Wolfe, Tarek Samir Shaath, Amit Om, George Franklin Cohen, Akash Gunjan
- Drug reaction with eosinophilia and systemic symptoms (DRESS) in the pediatric population: A systematic review of the literature
- Grace Y. Kim, Katelyn R. Anderson, Dawn M.R. Davis, Jennifer L. Hand, Megha M. Tollefson
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?